MSA atypical antipsychotics
01 Feb Communication to industry on metformin-containing medicines
Posted at 09:34h
in
This document has been archived....
01 Feb Communication to industry on ranitidine-containing medicines
Posted at 09:31h
in
This document has been archived....
01 Feb DIPHENHYDRAMINE-CONTAINING MEDICINES
Posted at 09:29h
in
SAHPRA alerts all healthcare professionals about the risk of serious heart problems, seizures, coma and death associated with the use of high doses of diphenhydramine containing medicines....
01 Feb A SIGNAL OF MYOCARDITIS / PERICARDITIS ASSOCIATED WITH PFIZER-BIONTECH’S COVID-19 VACCINE, COMIRNATY (BNT162B2)
Posted at 09:27h
in
The South African Health Products Regulatory Authority (SAHPRA) would like to inform you of a signal of myocarditis / pericarditis associated with Pfizer-BioNTech’s ...
01 Feb Communication to industry on Post Marketing Reporting of ADRs guideline
Posted at 09:17h
in
The South African Health Products Regulatory Authority (SAHPRA), have reviewed the Post Marketing Reporting of ADR guideline following concerns raised by the industry on version 7 of the guideline published September 2020. In addition to the review, SAHPRA conducted a webinar with holders of...
28 Jan SAHPRA survey to determine company turnover
Posted at 14:29h
in
SAHPRA will be embarking on a survey to determine the latest annual company turnover of licence holders to understand the impact of inspection fees on the licence holders within local industry....
28 Jan GMP CERTIFICATES FOR CANNABIS CULTIVATED BY CULTIVATORS HOLDING A SECTION 22C(1)(b) LICENCE (LICENCE TO CULTIVATE CANNABIS FOR THE PURPOSES OF PRODUCING SCHEDULED SUBSTANCES)
Posted at 14:27h
in
Applicants who are in possession of a Licence to Cultivate Cannabis for Purposes of Producing Scheduled Substances in terms of section 22C(1)(b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) may apply for a GMP certificate for their facility. ...